A study published in PubMed reveals specific molecular profiling of secreted rheumatoid factors in patients with Sjögren's disease who also have lymphoma. This research could enhance understanding of the disease's pathology and inform future therapeutic strategies.

Roche partners with Simcere Zaiming in a $1.5 billion deal to develop a T cell engager targeting B cell-mediated diseases, including lymphoma and autoimmune conditions. This collaboration aims to leverage innovative therapies for a range of serious health issues.

A case study highlights the unusual sequential development of multiple sclerosis, thymoma, myasthenia gravis, and lymphoma in a single patient. This rare combination of conditions may provide insights into the interplay between autoimmune diseases and malignancies.

New research reveals that inherited genetics can significantly impact the safety and efficacy of CAR-T cell therapy for blood cancers like lymphoma. Conducted by Mass General Brigham Cancer Institute and others, the study highlights the need for personalized approaches in CAR-T cell treatment to mitigate side effects and enhance patient outcomes.

Early data from Legend's in vivo lymphoma cell therapy shows promising results, with all recipients experiencing reduced or eliminated disease signs. This positions the therapy as a potential competitor to existing ex vivo treatments like Novartis' Kymriah.